Immunome, Inc.
NASDAQ:IMNMBiotechnology
Healthcare
$16.61 -2.26%
-$0.42 today
- Market cap
- $1.96B
- Beta
- 2.07
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.99
52W Low $7.96High $27.65
Volume 0.88M
Average 1.23M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$190.92M
FY 2025 · Annual
Investing Cash Flow
$60.80M
FY 2025 · Annual
Financing Cash Flow
$640.36M
FY 2025 · Annual
+166.2% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (24.71M) | (36.9M) | (106.81M) | (292.96M) | (212.39M) |
| Depreciation & Amortization | 755K | 631K | 728K | 2.1M | 2.96M |
| Deferred Income Tax | (500K) | (7.27M) | 0 | 0 | 0 |
| Stock-Based Compensation | 3.45M | 5.33M | 6.22M | 15.75M | 25.69M |
| Change in Working Capital | 2.78M | 2.24M | 12M | 14.87M | (15.23M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.78M | (677K) | (608K) | 9.53M | (9.16M) |
| Other Working Capital | 998K | 2.92M | 12.61M | 5.35M | (6.06M) |
| Other Non-Cash Items | 4K | 7.27M | 80.29M | 149.45M | 8.06M |
| Operating Cash Flow | (18.23M) | (28.69M) | (7.57M) | (110.79M) | (190.92M) |
| Capital Expenditures | (79K) | (248K) | (831K) | (53.51M) | (9.69M) |
| Acquisitions (Net) | 0 | 0 | 9.28M | 0 | 0 |
| Purchases of Investments | 0 | 0 | (38.93M) | (186.56M) | (123.27M) |
| Sales of Investments | 0 | 0 | 0 | 155M | 200M |
| Other Investing Activities | 0 | 0 | 0 | (46.34M) | (6.25M) |
| Investing Cash Flow | (79K) | (248K) | (30.48M) | (85.06M) | 60.8M |
| Debt Repayment | (113K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 27.23M | 32K | 34K | 250M | 640.36M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 656K | 0 | 116.37M | (9.47M) | 0 |
| Financing Cash Flow | 27.77M | 32K | 116.41M | 240.53M | 640.36M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 9.46M | (28.91M) | 78.36M | 44.67M | 510.24M |
| Free Cash Flow | (18.31M) | (28.94M) | (8.4M) | (164.3M) | (200.6M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$212.4M
+ D&A$3.0M
+ Stock-Based Comp$25.7M
+ Deferred Tax$0
- Working Capital-$15.2M
+ Other Non-Cash$8.1M
= Operating Cash Flow-$190.9M
- Capex-$9.7M
= Free Cash Flow-$200.6M
Analysis
FY2025 free cash flow is -$200.6M. FCF conversion is 94.4% of net income. Operating cash flow was -$190.9M, with capex of -$9.7M. The largest bridge item is Stock-Based Comp at $25.7M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| S-3ASR | S-3ASR filing | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| S-3ASR | S-3ASR filing | Nov 9, 2026 | |
| SC 13G | SC 13G filing | Oct 30, 2026 |
Does IMNM generate free cash flow?
Immunome, Inc. (IMNM) generated -$200.60M of free cash flow in fiscal 2025.
How much operating cash flow does IMNM produce?
Operating cash flow was -$190.92M, before capital expenditures of $9.69M.
Continue the stock analysis
Jump to another research area for this company.